Yeah it is tough listening to the bashers and now

Yeah it is tough listening to the bashers and now being able to address the real reason they are posting.

Here is A17 posting in his other biotechs that he is invested in. He is either short, loves suffering, or the worst investor of all time.

AVXL -2/9

Quote:

---

I heard this for last 3 years - it has not moved out of pre-clinical status- it is not on milestone for this year. So don’t fool yourself.

As an investor, I would take one success in PDD this year to see stock price jump

---

ARTH - 2/13

Quote:

---

Actually not so good
- cash on hand $3.4 million
- they are trying to mfr product on commercial scale - which means they have no partner
- they are trying to go to internal applications which is good but long term -

SP will continue to go down

---

GALT 2/15

Quote:

---

Don’t be so sure. This move is based on GILD CX trial failure.

The co has no progress or no positive news. They cannot even start trial unless they get a partner and then funding.

So unless there is actual news on partnership or BO the SP will go down.

---